Erdheim-Chester病:MAPK通路突变与靶向治疗进展
ECD以泡沫样CD68+CD1a-组织细胞浸润为特征,自1930年以来已知1500例。超过80%患者存在MAPK通路激活突变,主要为BRAFV600E(57%-70%)和MAP2K1(近20%)。2016年分类将ECD与LCH归为「L」组炎症性髓系肿瘤。干扰素-α似为最佳初始治疗,BRAF/MEK抑制剂对多系统或难治性ECD高效。
要点
- ECD中超过80%存在MAPK通路激活突变,BRAFV600E占57%-70%。
- 长骨受累见于80%-95%患者,是ECD最突出表现之一。
- 中枢神经系统受累是强预后因素和独立死亡预测因子。
核心结论
- ECD是炎症性髓系肿瘤,MAPK通路激活突变常见,BRAF/MEK抑制剂高效且疗效可重复,但应保留用于最严重表现。
研究设计与样本
- 综述,自1930年以来已知1500例ECD患者。
主要发现
- 超过80%的ECD患者存在MAPK通路激活突变,其中BRAFV600E占57%-70%,MAP2K1占近20%。
- 长骨受累见于80%-95%的患者,CT示「毛发肾」征占63%,主动脉「包被」征占40%,右心房假瘤性浸润占36%。
- 中枢神经系统受累是强预后因素和独立死亡预测因子。
- 自2012年以来,全球超过200例多系统或难治性ECD患者从BRAF和MEK抑制剂治疗中获益。
关键数值与推荐
- ECD诊断依据泡沫样CD68+CD1a-组织细胞浸润组织。
- 2016年组织细胞增生症分类修订将LCH和ECD归入「L」组,二者均被视为炎症性髓系肿瘤。
- 干扰素-α似乎是ECD最佳的初始治疗。
- BRAF和MEK抑制剂对ECD具有总体、稳健且可重复的疗效,迄今未出现获得性耐药。
临床怎么用
- ECD患者应评估MAPK通路突变状态,尤其是BRAFV600E和MAP2K1。
- 干扰素-α可作为ECD的初始治疗选择。
- BRAF/MEK抑制剂可用于多系统或难治性ECD,但需权衡严重不良反应和未知长期后果,保留给最严重表现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Erdheim-Chester disease (ECD) is characterized by the infiltration of tissues by foamy CD68+CD1a- histiocytes, with 1500 known cases since 1930. Mutations activating the MAPK pathway are found in more than 80% of patients with ECD, mainly the BRAFV600E activating mutation in 57% to 70% of cases, followed by MAP2K1 in close to 20%. The discovery of BRAF mutations and of other MAP kinase pathway alterations, as well as the co-occurrence of ECD with LCH in 15% of patients with ECD, led to the 2016 revision of the classification of histiocytoses in which LCH and ECD belong to the "L" group. Both conditions are considered inflammatory myeloid neoplasms. Ten percent of ECD cases are associated with myeloproliferative neoplasms and/or myelodysplastic syndromes. Some of the most striking signs of ECD are the long bone involvement (80%-95%), as well as the hairy kidney appearance on computed tomography scan (63%), the coated aorta (40%), and the right atrium pseudo-tumoral infiltration (36%). Central nervous system involvement is a strong prognostic factor and independent predictor of death. Interferon-α seems to be the best initial treatment of ECD. Since 2012, more than 200 patients worldwide with multisystem or refractory ECD have benefitted from highly effective therapy with BRAF and MEK inhibitors. Targeted therapies have an overall, robust, and reproducible efficacy in ECD, with no acquired resistance to date, but their use may be best reserved for the most severe manifestations of the disease, as they may be associated with serious adverse effects and as-yet-unknown long-term consequences.
引用
- Haroche J, Cohen-Aubart F, Amoura Z, et al. Erdheim-Chester disease. Blood. 2020. PMID: 32107533. doi:10.1182/blood.2019002766
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。